Research on the Impact of Drug Centralized Purchase System on the Performance of Chinese Pharmaceutical Enterprises

Abstract

As an important industry to maintain life and health and social stability, the pharmaceutical industry has always been the focus of the whole society. The centralized pharmaceutical procurement policy implemented in China since 2019 has effectively solved the problem of "supporting doctors with medicine", but there is still a lack of academic research on its impact on the performance of pharmaceutical enterprises. Therefore, this study uses the case analysis method to analyze the financial data of 8 representative enterprises in the field of chemical medicine, high value consumables and biological products (insulin) to study the impact of policies. The study found that the centralized procurement policy has a significant effect on the price decline and market share increase. In the short term, it will have a certain impact on the performance of pharmaceutical enterprises, and different enterprises in different sub industries will be affected differently due to different sizes. In the long run, it will be conducive to the development of pharmaceutical enterprises and promote the standardization and centralization of the pharmaceutical market.